1.Correlation between serum lncRNA MALAT1 and leptin in patients with multiple myeloma
Changming SUN ; Zongfang PIAO ; Yufeng GUO ; Ran LI ; Liping WANG ; Weichuan ZHAO
Chongqing Medicine 2024;53(20):3090-3094,3099
Objective To investigate the relationship between the expression levels of long non-coding RNA(lncRNA)metastasis-associated lung adenocarcinoma transcript 1(MALAT1)and leptin levels in the patients with multiple myeloma,as well as the role in the diagnosis and prognosis of multiple myeloma.Meth-ods A total of 60 patients with newly diagnosed multiple myeloma in this hospital from January 2018 to Oc-tober 2020 were selected as the patient group.Additionally,60 healthy individuals during the same period were recruited as the control group.The levels of serum lncRNA MALAT1 and leptin in the test population were detected.The correlation between the two and thier ratio as well as their role in disease prognosis were invest-gated.Results The expression levels of serum lncRNA MALAT1 and leptin in the patients group were signif-icantly higher than those in the control group,and the difference was statistically significant(P<0.05).A-mong the various stages of Durie-Salmon(DS)staging,the expression levels of lncRNA MALAT1 and leptin from stage I,stage Ⅱ and stage Ⅲ were in turn from high to low,and the differences were statistically signifi-cant(P<0.05).Among different immune types,the expression level of lncRNA MALAT1 in the patients with light chain type was highest,which in those with non-secretory type was lowest.The leptin levels in the patients with light chain type,IgG type,IgA type and non-secretory type were in turn from high to low,and the differences were statistically significant(P<0.05).Furthermore,the expression level of lncRNA MAL-AT1 was positively correlated with leptin(r=0.41,P<0.05).There were statistically significant differences in the expression levels of lncRNA MALAT1,leptin levels,and lncRNA MALAT1/leptin ratio between before and after treatment in the patients with treatment effect(P<0.05).However,there was no statistically sig-nificant difference in these two indices between before and after treatment in the patients with no treatment effect(P>0.05).After treatment,the median survival time for the patients with serum lncRNA MALAT1/leptin ratio<3 was 27 months(95%CI:21.949-27.120),while which for the patients with serum lncRNA MALAT1/leptin ratio 3 was 14 months(95%CI:12.076-22.199),and the difference was statistically sig-nificant(P=0.014).Conclusion lncRNA MALAT1 and leptin exhibit a certain extent of synergistic effect in the de-velopment and progression of multiple myeloma.The ratio of these two could be used to evaluate the prognosis of the patients.
2.Sufentanil promotes autophagy and improves ischemia -reperfusion -induced acute kidney injury via up -regulating microRNA -145.
Yan LU ; Zongfang PIAO ; Jianling LI ; Ling LI ; Ruhong LI
Journal of Central South University(Medical Sciences) 2022;47(10):1315-1323
OBJECTIVES:
Sufentanil has a good protective effect on myocardial and liver injury caused by ischemia reperfusion (IR), but its protective effect on kidney is still unclear. This study aims to investigate whether sufentanil can prevent IR-induced acute kidney injury (AKI) and to determine whether its efficacy is related to miR-145-mediated autophagy.
METHODS:
A total of 40 rats were randomly divided into 5 groups (n=8 in each group): A sham group, an IR group, a sufentanil group, a sufentanil+miR-145 inhibitor control group (an anti-NC group) and a sufentanil+miR-145 inhibitor group (an anti-miR-145 group). Except for the sham group, the other groups established a rat AKI model induced by IR. The sufentanil group, the sufentanil+anti-NC group, and the sufentanil+anti-miR-145 were injected with sufentanil (1 μg/kg) through femoral vein 30 min before ischemia. The sufentanil+anti-NC group and the sufentanil+anti-miR-145 group were injected with miR-145 inhibitor control or anti-miR-145 (80 mg/kg) through the tail vein before sufentanil pretreatment. The structure and function of kidneys harvested from the rats were evaluated, and the protein levels of autophagy-related proteins, oxidative stress levels, and apoptosis levels were measured.
RESULTS:
Compared with the IR group, the renal structure and function were improved in the sufentanil group. The levels of blood urea nitrogen (BUN), creatinine (Cr), urinary kidney injury molecule 1 (KIM-1), neutrophil gelatinase related lipid transporter (NGAL), tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6 and ROS were significantly decreased (all P<0.05). In addition, compared with the IR group, the levels of Beclin-1 and LC3 in renal tissues in the sufentanil group were significantly increased (both P<0.05), and the apoptosis in renal tissues was significantly reduced (P<0.05). Compared with the sufentanil+anti-NC group, the levels of BUN, Cr, KIM-1, NGAL, TNF-α, IL-1β, IL-6 and ROS in the sufentanil+anti-miR-145 group were significantly increased (all P<0.05), the levels of Beclin-1 and LC3 in renal tissues were significantly decreased (both P<0.05), and the apoptosis in renal tissues was significantly increased (P<0.05).
CONCLUSIONS
Sufentanil can prevent the AKI induced by IR, which is related to the up-regulation of miR-145-mediated autophagy.
Animals
;
Rats
;
Acute Kidney Injury/pathology*
;
Antagomirs
;
Autophagy
;
Beclin-1/metabolism*
;
Creatinine
;
Interleukin-6/metabolism*
;
Ischemia
;
Kidney/pathology*
;
Lipocalin-2
;
MicroRNAs/metabolism*
;
Reactive Oxygen Species
;
Reperfusion
;
Reperfusion Injury/metabolism*
;
Sufentanil/therapeutic use*
;
Tumor Necrosis Factor-alpha
;
Up-Regulation